<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027061</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-771</org_study_id>
    <nct_id>NCT05027061</nct_id>
  </id_info>
  <brief_title>A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan</brief_title>
  <official_title>Retrospective Medical Chart Review Study for Non-valvular Atrial Fibrillation Patients Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to understand real-world oral anticoagulants (OAC)&#xD;
      (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial&#xD;
      fibrillation (NVAF) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specialization of the treating physician</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of NVAF participants: Age group</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of NVAF participants: Gender</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of NVAF participants: Body weight</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of NVAF participants: Height</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Drinking information</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Smoking information</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Exercise information</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Internal medical device information</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcome of NVAF participants: Degree of life freedom</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Hospitalization/outpatient status</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of NVAF participants: Risk factors for stroke/bleeding</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of NVAF participants: Comorbidities</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: OAC prescription and administration status</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: beta blocker</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: amiodarone</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: Statin</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: proton pump inhibitor (PPI)</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: H2-receptor antagonist</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: aspirin</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of medication prescribed during baseline: other anticoagulants</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of outcomes of NVAF participants: Pulse rate</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Non-Valvular Atrial Fibrillation (NVAF)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Apixaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Edoxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <description>Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulants</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        An estimated 12,000 NVAF patients' medical charts within the identification period&#xD;
        01-July-2010 to the latest date of data availability in 2019 are expected to fulfill the&#xD;
        study eligibility criteria.&#xD;
&#xD;
          -  Sub-population 1: Non-valvular atrial fibrillation (NVAF) participants receiving oral&#xD;
             anticoagulants&#xD;
&#xD;
          -  Sub-population 2: Non-valvular atrial fibrillation (NVAF) participants not receiving&#xD;
             oral anticoagulants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals â‰¥ 20 years old as of the index date&#xD;
&#xD;
          -  At least 1 diagnosis of NVAF during index date, identified by any medical record&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had no data of serum creatinine in the patient's medical records&#xD;
&#xD;
          -  Had no data of body weight in the patient's medical records&#xD;
&#xD;
          -  Were given OAC for treatment of diseases other than AF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <zip>1070052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-562247</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Oral Anticoagulants</keyword>
  <keyword>Japan</keyword>
  <keyword>Retrospective Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

